查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947954

Enzalutamide錠市場依治療階段、最終用戶、適應症、通路和劑量分類，全球預測，2026-2032年

Enzalutamide Tablets Market by Therapy Line, End User, Indication, Distribution Channel, Dosage Strength - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，Enzalutamide片劑市場價值將達到 37.2 億美元，到 2026 年將成長至 38.8 億美元，到 2032 年將達到 52.8 億美元，複合年成長率為 5.10%。

關鍵市場統計數據
基準年 2025 37.2億美元
預計年份：2026年 38.8億美元
預測年份 2032 52.8億美元
複合年成長率 (%) 5.10%

本文簡要概述了Enzalutamide片劑的臨床特徵和相關人員趨勢如何重塑治療決策和獲取途徑。

Enzalutamide片已成為多種前列腺癌適應症的口服治療主力藥物，其臨床特性持續影響治療流程、支付方考量和採購慣例。本文概述了Enzalutamide片在現代腫瘤治療中的作用，並重點闡述了其作用機制、給藥便利性和不斷擴大的適應症如何影響處方醫生的決策和下游相關人員的行為。

對不斷演變的臨床證據、支付方評估框架以及供應鏈創新進行深入分析，這些因素正在重新定義口腔癌藥物的採用和取得。

由於臨床證據的不斷完善、指南的更新以及以患者為中心的護理模式的廣泛應用，Enzalutamide片劑的治療格局正在發生變革性變化。隨著新的臨床試驗結果不斷完善口服雄性激素受體抑制劑的相對優勢，臨床醫生正在重新調整治療方案，並在某些患者群體中更早使用該類藥物。這種轉變促使人們更加關注耐受性管理、藥物交互作用的監測以及能夠保留後續治療選擇的治療順序策略。

從實際檢驗2025年美國關稅政策變化如何影響癌症治療藥物供應的籌資策略、採購慣例和營運彈性

美國2025年實施的關稅政策調整的累積效應，已對進口原料藥和Enzalutamide片劑的成本動態和供應鏈結構產生了顯著影響。製造商和經銷商正採取措施降低進口關稅帶來的風險，包括重新評估其採購基地、協商修訂後的供應商協議以及加快本地生產評估。這些調整需要採購、監管和銷售團隊之間的跨職能合作，以維持供應的連續性並確保商業性可行性。

多維細分分析揭示了治療線、終端使用者組成、適應症組成、通路和劑量強度如何影響需求促進因素和營運重點。

關鍵細分分析揭示了按治療方案、最終用戶、適應症、分銷管道和劑量強度分類的不同需求模式和相關人員優先事項。就治療方案而言，第一線治療方案的選擇受最新指南更新和一線對照藥物療效的影響；二線治療方案的使用反映了治療順序邏輯和既往激素暴露史；三線治療方案的趨勢則受耐受性和累積暴露量的影響。這些臨床決策因素直接影響採購頻率和藥品目錄協商。

從全面的區域觀點闡述監管多樣性、支付方框架和分銷基礎設施如何影響美洲、歐洲、中東和非洲以及亞太地區的准入策略。

區域趨勢將顯著影響美洲、歐洲、中東和非洲以及亞太地區的醫療服務取得途徑、監管應對措施和商業策略。在美洲，重點在於整合醫療系統與私人支付者之間的談判，這將指導藥品目錄的製定和病患援助計畫的設計。同時，集中式集團採購組織和大型醫院網路在競標結果和採購速度方面發揮關鍵作用。過渡性政策和區域報銷框架要求制定客製化的價值提案，使臨床數據與支付方特定的療效指標相符。

對產業相關人員為保持差異化優勢和擴大口服抗癌藥物的可及性而採取的競爭策略、夥伴關係模式和監管應對措施進行評估性總結

主要企業的競爭策略和企業策略體現了生命週期管理、實證醫學證據產生和夥伴關係模式的結合，旨在保持臨床差異化並擴大市場准入。創新企業優先進行長期安全性和療效比較研究，以支持擴大適應症並維持其在藥品目錄中的地位，同時也投資於病患援助計畫和數位依從性解決方案。同時，尋求學名藥和生物相似藥途徑的企業則專注於擴大生產規模、提交監管替代性文件以及製定具有競爭力的定價策略，以搶佔對價格最敏感的細分市場。

為商業、臨床和供應鏈領導者提供切實可行的策略挑戰，以協調證據產生、合約簽訂和採購，從而實現穩健的市場准入和應用。

為確保持續的市場可及性和臨床應用，產業領導者應優先考慮整合臨床證據、商業策略和供應鏈韌性的方法。首先，他們應投資於有針對性的證據生成，以滿足支付方定義的價值標準和臨床醫生的關注點。這包括真實世界安全性監測和病患報告結果（PRO），從而加強處方箋和指南採納的證據基礎。其次，他們應實現採購多元化，並考慮建立策略性製造夥伴關係，以降低關稅風險和物流中斷的影響，同時確保產品品質和合規性。

透明的檢驗調查方法框架，詳細說明了關鍵相關人員的參與、二手證據的綜合、三角測量技術以及用於產生可操作結果的驗證程序。

這些研究結果所依據的調查方法結合了對同行評審的臨床文獻、指南聲明和監管文件的系統性回顧，以及對透過針對臨床醫生、醫院藥劑師、採購專業人員和行業高管的訪談收集到的相關人員觀點的結構化綜合分析。主要定性訪談旨在了解不同醫療機構的決策促進因素、未滿足的需求和營運挑戰，而次要資訊則提供了臨床和監管背景，以便準確解讀相關人員的觀點。

權威的綜合分析強調，需要採取臨床、商業和運作相結合的綜合方法，以確保患者獲得治療並持續接受治療。

總之，Enzalutamide片劑目前面臨的挑戰包括：臨床進展不斷匯聚、支付方預期不斷變化，以及貿易政策和分銷動態導致營運複雜性日益增加。積極主動地將循證醫學證據與支付方需求相結合、加強供應鏈冗餘、並根據不同終端用戶的行為調整商業性策略的相關人員，將更有利於維持藥物可及性並支持患者獲得永續的治療效果。臨床定位、採購機制和區域監管差異之間的相互作用，需要製定針對特定國家的細化實施計劃，並輔以集中化的策略監督。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章Enzalutamide片劑市場依治療階段分類

  • 一線治療
  • 二線治療
  • 三線治療

第9章Enzalutamide片劑市場：依最終用戶分類

  • 醫院藥房
  • 零售藥房
  • 專科診所
    • 腫瘤診所
    • 泌尿系統診所

第10章Enzalutamide片劑市場依適應症分類

  • 轉移性去勢去勢抗性前列腺癌
  • 轉移性荷爾蒙敏感性前列腺癌
  • 非轉移性去勢抗性前列腺癌

第11章Enzalutamide片劑市場（依分銷管道分類）

  • 線上
    • 製造商官方網站
    • 電子商務平台
  • 離線

第12章Enzalutamide片劑市場：依劑量分類

  • 120 mg
  • 160 mg
  • 40 mg
  • 80 mg

第13章Enzalutamide錠市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章Enzalutamide片劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國Enzalutamide錠劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國：Enzalutamide片市場

第17章：中國Enzalutamide片市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alkem Laboratories Ltd.
  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cadila Healthcare Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Limited
  • Hetero Labs Limited
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Lupin Limited
  • Mylan NV
  • Natco Pharma Limited
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-4F7A6D4FB6A4

The Enzalutamide Tablets Market was valued at USD 3.72 billion in 2025 and is projected to grow to USD 3.88 billion in 2026, with a CAGR of 5.10%, reaching USD 5.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.72 billion
Estimated Year [2026] USD 3.88 billion
Forecast Year [2032] USD 5.28 billion
CAGR (%) 5.10%

A concise strategic overview of how the clinical profile and stakeholder dynamics of enzalutamide tablets are reshaping treatment decisions and access pathways

Enzalutamide has emerged as a cornerstone oral therapy across multiple prostate cancer indications, and its clinical profile continues to shape treatment algorithms, payer deliberations, and procurement practices. This introduction outlines the therapeutic role of enzalutamide within contemporary oncology care, highlighting how its mechanism of action, administration convenience, and evolving label expansions inform prescriber decision making and downstream stakeholder behavior.

Practicing clinicians, hospital pharmacists, and specialty clinic teams are navigating an increasingly complex intersection of efficacy evidence, tolerability considerations, and health system budget pressures. Consequently, understanding the pathway from clinical trial results to real-world prescribing patterns is essential for manufacturers and distributors aiming to optimize product access and continuity of supply. Moreover, the interdependencies between regulatory updates, guideline revisions, and payer coverage rules necessitate a clear, evidence-based narrative to support adoption.

Finally, this introduction frames the subsequent sections: the shifting landscape of treatment paradigms, trade and tariff implications, segmentation-based demand drivers, regional dynamics, competitive positioning, strategic recommendations, and the research approach used to assemble these insights. Taken together, these elements provide a foundation for actionable strategy without presuming one-size-fits-all solutions, instead emphasizing context-specific planning and cross-stakeholder alignment.

An in-depth analysis of evolving clinical evidence, payer assessment frameworks, and supply chain innovations that are redefining adoption and access for oral oncology therapies

The therapeutic landscape for enzalutamide is experiencing transformative shifts driven by clinical evidence maturation, guideline updates, and a broader emphasis on patient-centric care models. As new trial outcomes refine the comparative positioning of oral androgen receptor inhibitors, clinicians are recalibrating line-of-therapy decisions and integrating earlier use in certain patient cohorts. This progression is accompanied by a heightened focus on tolerability management, drug-drug interaction vigilance, and sequencing strategies that preserve subsequent therapeutic options.

Concurrently, payers and health technology assessment bodies are adopting more granular value frameworks that consider not only clinical endpoints but also patient-reported outcomes and real-world safety profiles. These evolving assessment criteria are prompting manufacturers and providers to generate differentiated evidence packages that speak to long-term disease control, quality-of-life measures, and care pathway efficiencies. In parallel, digital health tools and remote monitoring practices are supporting adherence and toxicity surveillance, enabling more decentralized models of follow-up care that can affect refill patterns and distribution channel utilization.

Supply chain resilience and procurement sophistication also represent transformative levers. Stakeholders increasingly design contingency plans, diversify sourcing, and negotiate value-based agreements that align financial incentives with clinical outcomes. Taken together, these shifts underscore the need for integrated strategies that combine clinical leadership, payer engagement, and operations planning to secure durable access and to optimize patient outcomes in a dynamic therapeutic environment.

A pragmatic examination of how 2025 tariff shifts in the United States have reshaped sourcing strategies, procurement practices, and operational resilience for oncology drug supply

The cumulative effect of tariff policy changes implemented in 2025 in the United States has materially altered cost dynamics and supply chain design for imported active pharmaceutical ingredients and finished-dose enzalutamide tablets. Manufacturers and distributors have responded by reassessing sourcing footprints, negotiating revised supplier contracts, and accelerating local manufacturing evaluations to mitigate exposure to import duties. These adjustments have required cross-functional coordination across procurement, regulatory affairs, and commercial teams to maintain continuity of supply while preserving commercial viability.

From a procurement perspective, hospitals and specialty clinics have reevaluated tender strategies and inventory buffering practices to account for increased landed costs and potential lead-time variability. Meanwhile, distributors and third-party logistics providers have expedited network redesigns that prioritize tariff-efficient routing and consolidation opportunities. In some cases, companies have explored contractual pass-through mechanisms or supplier co-investment models to stabilize gross margins without compromising patient access.

Regulatory and compliance teams have been tasked with ensuring that any shifts in manufacturing location or supply chain partners adhere to current good manufacturing practices and product registration requirements. In addition, payer-contracting teams are working to reframe reimbursement conversations to reflect changed unit economics and to justify formulary positioning through robust value narratives. Ultimately, the 2025 tariff environment has reinforced the importance of integrated commercial-operational planning, where trade policy considerations are embedded in product lifecycle strategies and procurement negotiations.

A multidimensional segmentation analysis revealing how therapy line, end-user configuration, indication mix, distribution pathways, and dosage strengths shape demand drivers and operational priorities

Key segmentation insights reveal distinct demand patterns and stakeholder priorities when analyzed across therapy line, end user, indication, distribution channel, and dosage strength. When therapy line is considered, first-line therapy adoption is influenced by recent guideline updates and frontline comparator performance, second-line usage reflects sequencing logic and prior exposure to hormonal agents, and third-line therapy dynamics are shaped by tolerability and cumulative exposure concerns. These layers of clinical decision making directly inform purchasing cadence and formulary negotiations.

End-user segmentation shows different operational and procurement behaviors among hospital pharmacies, retail pharmacies, and specialty clinics. Hospital pharmacies include government and private hospital settings that often manage high-volume procurement cycles and institutional tendering procedures, while retail pharmacies divide between chain and independent outlets with differing purchasing power and refill logistics. Specialty clinics, encompassing oncology and urology clinics, tend to focus on therapy-specific clinical monitoring, adherence counseling, and direct patient support programs that affect prescription retention and follow-up care.

Indication-based differentiation underscores how metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and non-metastatic castration-resistant prostate cancer each present unique clinical objectives, monitoring requirements, and payer negotiation points. Distribution channel segmentation further nuances access pathways: direct tenders-operationalized through national and regional tenders-favor institutional procurement scale, hospital pharmacy purchases-whether via direct procurement or public tenders-reflect institutional buying practices, and online pharmacies-represented by manufacturer websites and third-party platforms-offer alternative fulfillment routes that influence patient convenience and adherence.

Finally, dosage strength segmentation across 120 mg, 160 mg, 40 mg, and 80 mg formulations impacts prescribing flexibility, inventory management, and unit-packaging strategies. Differences in strength availability can drive prescribing preferences when clinicians balance efficacy, tolerability, and pill burden, and can also influence packaging and distribution decisions to optimize shelf life and reduce waste. Collectively, these segmentation lenses provide a multidimensional view of where targeted commercial interventions and operational investments will yield the greatest return in access and patient support.

A comprehensive regional perspective describing how regulatory diversity, payer frameworks, and distribution infrastructures shape access strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics significantly affect access pathways, regulatory navigation, and commercial tactics across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, the emphasis on integrated health systems and private-payer negotiations steers formulary positioning and patient assistance program design, while centralized group purchasing organizations and large hospital networks play pivotal roles in tender outcomes and procurement cadence. Transitional policies and regional reimbursement frameworks necessitate tailored value communications that align clinical data with payer-specific outcome measures.

Across Europe, the Middle East & Africa, a heterogeneous regulatory landscape combines national health systems, private payers, and emerging reimbursement authorities, each of which evaluates clinical value through a mix of cost-effectiveness thresholds and real-world evidence. In many countries within this region, price negotiation and HTA-led assessments drive access timelines, requiring manufacturers to prepare locally relevant dossiers and to engage early with key opinion leaders to facilitate guideline inclusion. Moreover, supply chain considerations such as cold-chain capacity and regional distribution hubs influence inventory strategies and delivery reliability.

The Asia-Pacific region presents a diverse set of market access conditions ranging from highly regulated national procurement frameworks to liberalized private markets. Regulatory acceleration programs in certain jurisdictions can enable faster registrations, yet parallel importation practices and variable reimbursement pathways necessitate carefully sequenced market entry plans. Local manufacturing partnerships and strategic licensing arrangements often play a critical role in establishing sustainable supply, while patient support initiatives and digital adherence tools can be particularly effective in markets with decentralized care delivery. Taken together, these regional insights call for granular, country-level execution plans that respect regulatory nuance and payer expectations while leveraging broader regional synergies.

An evaluative synopsis of competitive maneuvers, partnership models, and regulatory strategies that industry players deploy to sustain differentiation and expand access for oral oncology agents

Competitive and corporate strategies among key companies reflect a mix of lifecycle management, evidence generation, and partnership models aimed at sustaining clinical differentiation and expanding access. Innovator companies prioritize long-term safety and comparative-effectiveness studies to support label expansions and to defend formulary placement, while also investing in patient support programs and digital adherence solutions. At the same time, players exploring generic or biosimilar pathways focus on manufacturing scale-up, regulatory interchangeability dossiers, and competitive pricing strategies to capture segments where cost sensitivity is highest.

Strategic collaborations between manufacturers, contract manufacturers, and distribution partners are increasingly common, enabling flexible scale management and improved responsiveness to demand variability. Licensing and co-promotion agreements can facilitate market entry in jurisdictions with complex regulatory or reimbursement landscapes, while joint ventures for local production address both tariff exposure and supply continuity. In addition, some companies are experimenting with value-based contracting or outcomes-linked agreements to share risk with payers and to strengthen real-world evidence generation.

Finally, intellectual property considerations, patent expiry timelines, and defensive life-cycle tactics such as new formulations or indication expansions inform the competitive calculus. Robust pharmacovigilance programs and proactive stakeholder engagement strategies bolster trust across clinicians and payers, while operational excellence in quality systems and regulatory compliance remains a non-negotiable foundation for maintaining market access and reputational integrity.

Actionable strategic imperatives for commercial, clinical, and supply chain leaders to align evidence generation, contracting, and sourcing for resilient access and adoption

Industry leaders should prioritize an integrated approach that aligns clinical evidence, commercial strategy, and supply chain resilience to secure durable access and to capture clinical adoption opportunities. First, invest in targeted evidence generation that addresses payer-defined value criteria and clinician concerns, including real-world safety monitoring and patient-reported outcomes, thereby strengthening the narrative for formulary inclusion and guideline engagement. Second, diversify sourcing and consider strategic manufacturing partnerships to mitigate tariff exposure and logistical disruptions while maintaining quality and regulatory compliance.

Next, tailor market access playbooks to end-user characteristics and distribution realities, recognizing that hospital pharmacies, retail pharmacies, and specialty clinics each require distinct support models ranging from institutional tender navigation to outpatient adherence programs. Additionally, prepare region-specific tactics that reflect local regulatory expectations and payer decision frameworks; in many cases, early engagement with key opinion leaders and health authorities will accelerate acceptance and reduce access friction. Finally, adopt flexible contracting approaches-such as performance-linked agreements or patient support co-funding-that align incentives across stakeholders and protect patient continuity of care.

By operationalizing these recommendations through cross-functional governance, centralized scenario planning, and prioritized investment in evidence and logistics, industry leaders can navigate uncertainty more effectively and convert clinical value into sustainable patient access.

A transparent methodological framework detailing primary stakeholder engagement, secondary evidence synthesis, triangulation techniques, and validation steps used to generate actionable findings

The research methodology underpinning these insights combined a systematic review of peer-reviewed clinical literature, guideline statements, regulatory documents, and a structured synthesis of stakeholder input gathered through targeted interviews with clinicians, hospital pharmacists, procurement specialists, and industry executives. Primary qualitative interviews were designed to surface decision drivers, unmet needs, and operational pain points across care settings, while secondary sources provided the clinical and regulatory context necessary to interpret stakeholder perspectives accurately.

Data triangulation was applied to reconcile differences between reported clinical trial outcomes and real-world practice patterns, and to validate thematic findings across multiple respondent groups. Analytical frameworks included segmentation mapping, supply chain risk assessment, and payer evidence gap analysis, each of which was used to translate observations into practical implications. The methodology also incorporated sensitivity checks and peer review by subject-matter experts to ensure interpretations remained robust and defensible.

Limitations of the approach are acknowledged, including the inherent variability of jurisdictional reimbursement processes and the evolving nature of clinical evidence. Wherever applicable, assumptions were clearly documented and cross-checked with stakeholders to minimize bias. Ethical research practices governed respondent recruitment and data handling, ensuring confidentiality and compliance with applicable standards.

A decisive synthesis highlighting the necessity of integrated clinical, commercial, and operational approaches to secure patient access and sustain therapeutic adoption

In conclusion, the current environment for enzalutamide tablets is defined by converging clinical advances, shifting payer expectations, and heightened operational complexity driven by trade policy and distribution dynamics. Stakeholders that proactively align evidence generation with payer needs, bolster supply chain redundancy, and tailor commercial approaches to segmented end-user behaviors will be best positioned to maintain access and to support sustained patient outcomes. The interplay between clinical positioning, procurement mechanisms, and regional regulatory variation requires granular, country-specific execution plans supported by centralized strategic oversight.

Moreover, competitive differentiation increasingly depends on holistic value propositions that combine clinical efficacy with patient support, reliable supply, and adaptive contracting models. Organizations that invest in these integrated capabilities can mitigate downside risk from tariff volatility, tender outcomes, and competitive pressures while creating clearer pathways for long-term uptake. Continued monitoring of guideline developments, real-world evidence, and payer policy shifts will be essential to refine tactics and to preserve both clinical relevance and commercial viability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enzalutamide Tablets Market, by Therapy Line

  • 8.1. First-Line Therapy
  • 8.2. Second-Line Therapy
  • 8.3. Third-Line Therapy

9. Enzalutamide Tablets Market, by End User

  • 9.1. Hospital Pharmacies
  • 9.2. Retail Pharmacies
  • 9.3. Specialty Clinics
    • 9.3.1. Oncology Clinics
    • 9.3.2. Urology Clinics

10. Enzalutamide Tablets Market, by Indication

  • 10.1. Metastatic Castration-Resistant Prostate Cancer
  • 10.2. Metastatic Hormone-Sensitive Prostate Cancer
  • 10.3. Non-Metastatic Castration-Resistant Prostate Cancer

11. Enzalutamide Tablets Market, by Distribution Channel

  • 11.1. Online
    • 11.1.1. Manufacturer Websites
    • 11.1.2. eCommerce Platforms
  • 11.2. Offline

12. Enzalutamide Tablets Market, by Dosage Strength

  • 12.1. 120 mg
  • 12.2. 160 mg
  • 12.3. 40 mg
  • 12.4. 80 mg

13. Enzalutamide Tablets Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Enzalutamide Tablets Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Enzalutamide Tablets Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Enzalutamide Tablets Market

17. China Enzalutamide Tablets Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alkem Laboratories Ltd.
  • 18.6. Astellas Pharma Inc.
  • 18.7. Aurobindo Pharma Limited
  • 18.8. Bayer AG
  • 18.9. Cadila Healthcare Limited
  • 18.10. Cipla Limited
  • 18.11. Dr. Reddy's Laboratories Ltd.
  • 18.12. Fresenius Kabi AG
  • 18.13. Glenmark Pharmaceuticals Limited
  • 18.14. Hetero Labs Limited
  • 18.15. Intas Pharmaceuticals Ltd.
  • 18.16. Johnson & Johnson
  • 18.17. Lupin Limited
  • 18.18. Mylan N.V.
  • 18.19. Natco Pharma Limited
  • 18.20. Pfizer Inc.
  • 18.21. Sun Pharmaceutical Industries Ltd.
  • 18.22. Teva Pharmaceutical Industries Ltd.
  • 18.23. Torrent Pharmaceuticals Ltd.
  • 18.24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENZALUTAMIDE TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENZALUTAMIDE TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY FIRST-LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY FIRST-LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY FIRST-LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY SECOND-LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY SECOND-LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY SECOND-LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY THIRD-LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY THIRD-LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY THIRD-LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY UROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY UROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ECOMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ECOMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY ECOMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 120 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 120 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 120 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 160 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 160 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 160 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 40 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 40 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 40 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 80 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 80 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY 80 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ENZALUTAMIDE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ENZALUTAMIDE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)